| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1993-05-19 |
| Identifiers | MRN HR-ML034-SYN; SSN (made up) 000-34-7158 |
| Document date | 2026-05-04 |
| Author | Samuel Adeyemi-Rourke, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Suspected pancreatic or duodenal cancer in a 32-year-old playwright with two months of epigastric pain boring through to the back, a 5 kg weight loss, black stools with iron deficiency anemia (hemoglobin 9.1 g/dL, ferritin 6 ng/mL), new diabetes (A1c 6.6%) and a cholestatic liver pattern. Upper endoscopy and pancreas-protocol CT are booked this week. Please see her within two weeks to review the results with her and plan treatment if cancer is found. [S]
Urgency: Urgent, within two weeks. [S]
Questions for the consultant:
Ms. Hansberry, 32, is seen at the request of Dr. Marchetti-Fields two weeks after she presented with two months of epigastric and back pain, weight loss, black stools with iron deficiency anemia, and new diabetes. Since then she has had an upper endoscopy, a pancreas-protocol CT, an endoscopic ultrasound with biopsy and a biliary stent, two doses of intravenous iron, and review at our pancreatic tumor board. The pain is 6 out of 10 and breaks her sleep; her stools are pale and float after fatty meals; there has been no black stool since the iron. She works at home as a playwright and is active most of the day (ECOG 1). She is not pregnant and has no children. She asked for the facts in plain words. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
5 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 2026-04-20 | active | S |
| Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart | 750 mg intravenously; two doses one week apart | Intravenous route | 2026-04-24 to 2026-05-01 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain | One tablet every 4 hours as needed | Oral route | 2026-05-04 | active | S |
| Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone | Two tablets at night | Oral route | 2026-05-04 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack | Two capsules with each meal, one with each snack | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |
| Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | C25.0 | S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md. |
| Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | E08.9 | S — Synthetic consequence of the synthetic tumor. |
| Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | K86.81 | S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer. |
| Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | G89.3 | S — Synthetic symptom of the synthetic tumor. |
| Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | active | confirmed | K83.1 | S — Synthetic consequence of the synthetic tumor. |
Vital signs recorded on 2026-05-04; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, tired, composed; weight 55.4 kg; blood pressure 108/68, pulse 92; ECOG 1 |
| Eyes | Slight scleral icterus, less than at the first visit |
| Abdomen | Epigastric tenderness without guarding; no mass, liver enlargement or ascites |
| Lymph nodes | No supraclavicular nodes; no umbilical nodule |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-04 | Hemoglobin [Mass/volume] in Blood | 10.4 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-05-04 | Leukocytes [#/volume] in Blood by Automated count | 7 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-04 | Neutrophils [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-05-04 | Platelets [#/volume] in Blood by Automated count | 366 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 119 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-04 | Glucose [Mass/volume] in Serum or Plasma | 141 | mg/dL | 70-99 mg/dL | High | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-35 U/L | Normal | S |
| 2026-05-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 8-35 U/L | Normal | S |
| 2026-05-04 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 168 | U/L | 35-104 U/L | High | S |
| 2026-05-04 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-04 | Albumin [Mass/volume] in Serum or Plasma | 3.5 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-04 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 486 | U/mL | <=35 U/mL | High | S |
| 2026-05-04 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 3.9 | ng/mL | Up to 3.0 ng/mL in non-smokers | High | S |
| 2026-05-04 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.8-1.2 | Normal | S |
| 2026-05-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-05-04 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 2026-05-04 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S |
Data reviewed: Dr. Marchetti-Fields's intake note and results. Upper endoscopy: an ulcerated, oozing mass on the medial wall of the second part of the duodenum beside the papilla, no peptic ulcer; biopsies: adenocarcinoma infiltrating from the pancreas. Pancreas-protocol CT with CT of the chest: 3.1 cm hypoattenuating mass in the pancreatic head invading the duodenum; common bile duct 13 mm and pancreatic duct 5 mm; contact with about 200 degrees of the superior mesenteric vein with short-segment narrowing that can be reconstructed; no contact with the superior mesenteric artery, celiac axis or common hepatic artery; no liver, peritoneal or lung lesion. EUS-guided biopsy: pancreatic adenocarcinoma, moderately differentiated; extra cores held for molecular profiling. ERCP: fully covered metal stent across a distal bile duct stricture. Today: bilirubin 0.9 mg/dL, alkaline phosphatase 168 U/L, CA 19-9 486 U/mL (after drainage), CEA 3.9 ng/mL, hemoglobin 10.4 g/dL, neutrophils 4.6, platelets 366, creatinine 0.68 mg/dL, albumin 3.5 g/dL, fasting glucose 141 mg/dL, INR 1.0. [S]